Screening for prostate cancer

Otis Brawley, Donna P. Ankerst, Ian M. Thompson

Research output: Contribution to journalReview article

Abstract

In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s, screening with the prostate-specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved treatment, has been uncertain. The recent release of 2 large randomized trials suggests that if there is a benefit of screening, it is, at best, small. Methods to assess a man's risk of prostate cancer, including those tools that integrate multiple risk factors, are now available and should be used in risk assessment. Men undergoing screening for prostate cancer may reduce their risk of prostate cancer with finasteride.

Original languageEnglish (US)
Pages (from-to)264-273
Number of pages10
JournalCA Cancer Journal for Clinicians
Volume59
Issue number4
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Prostatic Neoplasms
His-His-His-His-His-His
Prostate-Specific Antigen
Finasteride
Hematologic Tests
Mortality
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Screening for prostate cancer. / Brawley, Otis; Ankerst, Donna P.; Thompson, Ian M.

In: CA Cancer Journal for Clinicians, Vol. 59, No. 4, 01.07.2009, p. 264-273.

Research output: Contribution to journalReview article

Brawley, O, Ankerst, DP & Thompson, IM 2009, 'Screening for prostate cancer', CA Cancer Journal for Clinicians, vol. 59, no. 4, pp. 264-273. https://doi.org/10.3322/caac.20026
Brawley, Otis ; Ankerst, Donna P. ; Thompson, Ian M. / Screening for prostate cancer. In: CA Cancer Journal for Clinicians. 2009 ; Vol. 59, No. 4. pp. 264-273.
@article{928c84a7836942098942da333983b3ee,
title = "Screening for prostate cancer",
abstract = "In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s, screening with the prostate-specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved treatment, has been uncertain. The recent release of 2 large randomized trials suggests that if there is a benefit of screening, it is, at best, small. Methods to assess a man's risk of prostate cancer, including those tools that integrate multiple risk factors, are now available and should be used in risk assessment. Men undergoing screening for prostate cancer may reduce their risk of prostate cancer with finasteride.",
author = "Otis Brawley and Ankerst, {Donna P.} and Thompson, {Ian M.}",
year = "2009",
month = "7",
day = "1",
doi = "10.3322/caac.20026",
language = "English (US)",
volume = "59",
pages = "264--273",
journal = "Ca-A Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Screening for prostate cancer

AU - Brawley, Otis

AU - Ankerst, Donna P.

AU - Thompson, Ian M.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s, screening with the prostate-specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved treatment, has been uncertain. The recent release of 2 large randomized trials suggests that if there is a benefit of screening, it is, at best, small. Methods to assess a man's risk of prostate cancer, including those tools that integrate multiple risk factors, are now available and should be used in risk assessment. Men undergoing screening for prostate cancer may reduce their risk of prostate cancer with finasteride.

AB - In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s, screening with the prostate-specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved treatment, has been uncertain. The recent release of 2 large randomized trials suggests that if there is a benefit of screening, it is, at best, small. Methods to assess a man's risk of prostate cancer, including those tools that integrate multiple risk factors, are now available and should be used in risk assessment. Men undergoing screening for prostate cancer may reduce their risk of prostate cancer with finasteride.

UR - http://www.scopus.com/inward/record.url?scp=67651109099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651109099&partnerID=8YFLogxK

U2 - 10.3322/caac.20026

DO - 10.3322/caac.20026

M3 - Review article

C2 - 19564245

AN - SCOPUS:67651109099

VL - 59

SP - 264

EP - 273

JO - Ca-A Cancer Journal for Clinicians

JF - Ca-A Cancer Journal for Clinicians

SN - 0007-9235

IS - 4

ER -